XRP2 Stock Chart & Stats
€9.50
-€0.50(-5.00%)
At close: 4:00 PM EDT
€9.50
-€0.50(-5.00%)
Day’s Range― - ―
52-Week Range€3.40 - €15.10
Previous CloseN/A
Volume0.00
Average Volume (3M)33.00
Market Cap
€685.02M
Enterprise Value€446.72
Total Cash (Recent Filing)€72.05M
Total Debt (Recent Filing)-€112.00K
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 17, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.19
Shares Outstanding60,209,360
10 Day Avg. Volume3
30 Day Avg. Volume33
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.61
Price to Sales (P/S)513.72
P/FCF Ratio-4.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€31.67Price Target Upside233.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.43
Revenue Forecast (FY)€453.39K
Bulls Say, Bears Say
Bulls Say
Positive Phase 2 EfficacyStrong Phase 2 efficacy and reduced phlebotomy requirements could support divesiran’s progression into Phase 3 and establish a differentiated treatment approach in polycythemia vera if durability and safety are confirmed.
Strengthened Funding RunwayThe substantial capital raise materially improves liquidity for clinical development and pipeline advancement, reducing immediate funding pressure and enabling Silence to pursue value-creating trials without relying solely on near-term partnerships.
Proprietary RNAi PlatformA proprietary delivery and chemistry toolbox can support repeatable development across genetically driven and cardiometabolic diseases, strengthening pipeline breadth and the potential for multiple partnered or wholly owned assets.
Bears Say
Revenue Volatility And CollapseThe sharp revenue reversal indicates that collaboration and licensing income is unpredictable and not yet supported by recurring product sales, making financial planning difficult and leaving results exposed to milestone timing.
Persistent Cash BurnSustained negative operating and free cash flow shows that development spending materially exceeds internally generated funds. Continued clinical investment will therefore depend on external financing or partnerships, creating execution and funding risk.
Negative Equity And Dilution RiskNegative equity reflects cumulative losses and weak capital formation, while the latest equity offering demonstrates the need for replenishment. Further raises may support operations but can dilute existing holders and signal ongoing capital dependence.
Silence Therapeutics News
XRP2 FAQ
What was Silence Therapeutics Plc’s price range in the past 12 months?
Silence Therapeutics Plc lowest stock price was €3.40 and its highest was €15.10 in the past 12 months.
What is Silence Therapeutics Plc’s market cap?
Silence Therapeutics Plc’s market cap is €685.02M.
When is Silence Therapeutics Plc’s upcoming earnings report date?
Silence Therapeutics Plc’s upcoming earnings report date is Nov 17, 2026 which is in 83 days.
How were Silence Therapeutics Plc’s earnings last quarter?
Silence Therapeutics Plc released its earnings results on Aug 10, 2026. The company reported -€0.077 earnings per share for the quarter, beating the consensus estimate of -€0.109 by €0.032.
Is Silence Therapeutics Plc overvalued?
According to Wall Street analysts Silence Therapeutics Plc’s price is currently Undervalued.
Does Silence Therapeutics Plc pay dividends?
Silence Therapeutics Plc does not currently pay dividends.
What is Silence Therapeutics Plc’s EPS estimate?
Silence Therapeutics Plc’s EPS estimate is -0.1.
How many shares outstanding does Silence Therapeutics Plc have?
Silence Therapeutics Plc has 60,209,360 shares outstanding.
What happened to Silence Therapeutics Plc’s price movement after its last earnings report?
Silence Therapeutics Plc reported an EPS of -€0.077 in its last earnings report, beating expectations of -€0.109. Following the earnings report the stock price went up 42.424%.
Which hedge fund is a major shareholder of Silence Therapeutics Plc?
Currently, no hedge funds are holding shares in DE:XRP2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Silence Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€31.67 (233.41% Upside)
€31.67 (233.41% Upside)
Blogger Sentiment
Bullish
DE:XRP2 Sentiment 80%
Sector Average 61%
Sector Average 61%
Technicals
SMA
Positive
20 days / 200 days
Momentum
90.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-35.60%
Trailing 12-Months
Company Description
Silence Therapeutics Plc
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
XRP2 Stock 12 Month Forecast
Average Price Target
€31.67
▲(233.41% Upside)